PitchSend

Investor Presentaiton

Positive Outlook 2020 Investments in MarinosolvⓇ and commercialisation of CarrageloseⓇ Further strong demand for Carragelose® products expected ■ Lab data and clinical data for Sars-CoV-2 are growth drivers ■ Full focus on conversion of data into marketing & sales Expansion of capacities continues. ◉ Ongoing discussions with renowned new partners marino med Marinosolv® products drive value further First deal for Budesolv expected in H2/2020 ■ New applications for nose, lung, eyes and gastrointestinal have huge potential for further growth Record revenues, solid financials and strong outlook for 2020 and beyond 16

View entire presentation